Meningococcal immunology

Immunology and Allergy Clinics of North America

Volumn 23, Issue 4, 2003, Pages 769-786

  Lepow, Martha L ^a   Hughes, Patricia A ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY B5; NEISSERIAL SURFACE PROTEIN A; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE VACCINE; PROTEIN FRPB; SEROGROUP A MENINGOCOCCAL POLYSACCHARIDE VACCINE; SEROGROUP C MENINGOCOCCAL POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; EPIDEMIC MENINGITIS; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION CONTROL; INFECTION RESISTANCE; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVACCINATION; REVIEW; VACCINATION;

EID: 0347993827     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8561(03)00092-4     Document Type: Review

References (90)

1. Willis T. A description of an epidemical fever in 1661. In: Practice of physick. London: T. Dring; 1684. p. 46-54.
2. Weichselbaum A. Ueber d ie aetiologie der akuten meningitis cerebro-spinal fort schr [in German]. Med 1887;5:573-83, 620-6.
3. Vieusseux M. sur le Maladie qui a regne a Geneva au Printemps de 1805 [in French]. J Med Clin Pharm 1805;11:163-82.
4. Schuchat A, Deaver-Robinson K, Wenger JD, Harrison LH, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997;337:970-6.
5. Rosenstein NE, Perkins BA, Stevens DS, et al. Medical progress: meningococcal disease. N Engl J Med 2001;344:1378-87.
6. Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996;15:967-79.
7. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-9.
8. Rosenstein NE, Perkins BA, Stephens DS. The changing epidemiology of meningococcal disease in the United States 1992-1996. J Infect Dis 1999;180:894-901.
9. Harrison L, Dwyer D, Maples C, Billman L. Risk of meningococcal infection in college students. JAMA 1999;281:1906-10.
10. Centers for Disease Control and Prevention. Meningococcal vaccine and college students: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mort Wkly Rep 2000;49:11-20.
11. Greenwood BM, Blakebrough IS, Bradley AK, Wali S, Whittle HC. Meningococcal disease and season in sub-Saharian Africa. Lancet 1984;1:1339-42.
12. Wilder-Smith A, Goh T, Barkham T, Paton N. Hajj Associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. CID 2003;36:679-83.
13. Popovic T, Sacchi CT, Reeves MW, Whitney AM, Mayer LW, Nobel CA, et al. Neisseria meningitidis serogroup W135 isolates associated with ET-37 complex. Emerg Infect Dis 2000;6:428-9.
14. Ashton EA, Ryan JA, Borczyk A, Cougant DA, Mancino L, Huang D. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 1991;29:2489-93.
15. Marin M, Diaz S, Rodriguiz-Creixems E, et al. Emergence of severe infections caused by serogroup C Neisseria meningitidis [abstract #K-131]. Proceedings of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997. p. 351.
16. Stephens DS. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999;353:941-2.
17. Filice GA, Hayes PS, Counts GW, et al. Risk of group A meningococcal disease: bacterial influence and cross reactive bacteria among mucosal flora. J Clin Microbiol 1985;22:152-6.
18. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 1984;63: 243-73.
19. Fijen CA, Kuijper EJ, Hannema AJ, Sjoholm AG, van-Putten JP. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. Lancet 1989;2:585-8.
20. Francke EL, Neu HC. Postsplenectomy infection. Surg Clin North Am 1981;61:135-55.
21. Stephens DS, Hajjeh RA, Baughman WS, Harvey RC, et al. Sporadic meningococcal disease in adults: results of a 5 year, population-based study. Ann Intern Med 1995;123:937-40.
22. Pinner RW, Onyango F, Perkins BA, Mirza NB, et al. Epidemic meningococcal disease in Nairobi, Kenya, 1989: The Kenya Centers for Disease Control (CDC) Meningitis Study Group. J Infect Dis 1992;166:359-64.
23. Musher DM. How contagious are common respiratory tract infections? N Engl J Med 2003;348: 1256-66.
24. Gauld JR, Nitz RE, Hurler DH, et al. Epidemiology of meningococcal meningitis at Fort Ord. Am J Epidemiol 1965;82:56-72.
25. Stuart JM, Cartwright KA, Robinson PM, Noah ND. Effect of smoking on meningococcal carriage. Lancet 1989;2:723-5.
26. Fischer M, Hedberg K, Cardosi P, et al. Epidemic meningococcal disease and tobacco smoke. Pediatr Infect Dis J 1997;16:979-83.
27. Moore PS, Hierholzer J, Dewitt W, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 1990;264:1271-5.
28. Caugant D, Heiby ZA, Froholm, et al. WHO collaborating center for reference and research on meningococci. Oslo, Norway: Department of Bacteriology, National Institute of Public Health.
29. Flexner S. The results of serum treatment in 1300 cases of epidemic meningitis. J Exp Med 1913;17:553-76.
30. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. The development of natural immunity. J Exp Med 1969;129:1327-48.
31. Griffiss JM, Brandt BL, Broud DD, Goroff DK, Baker CJ. Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis 1984;150: 71-9.
32. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus I. The role of humoral immunity. J Exp Med 1969;129:1307-26.
33. Gold R, Lepow ML. Present status of polysaccharide vaccines in the prevention of meningococcal disease. Adv Pediatr 1976;23:71-87.
34. Scherp HW, Rake G. Studies on meningococcal infection. XIII. Correlation between antipolysaccharide and the antibody which protects mice against infection with type I meningococci. J Exp Med 1945;8:85-92.
35. Kabot EA, Kaiser H, Sikarski H. Preparation of the type specific polysaccharide of the type I meningococcus and a study of its effectiveness as an antigen in human beings. J Exp Med 1944; 80:229-307.
36. Artenstein MS, Schneider H, Tingley MD. Prevalence of serogroups causing disease in US army personnel. Bull World Health Organ 1971;45:275-8.
37. Gotschlich EC, Liu TY, Artenstein MS. Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J Exp Med 1969;129:1349-65.
38. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to Group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987;138:4402-7.
39. Gotschlich EC, Rey M, Triau R, Sparks KJ. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest 1972;51:89-96.
40. Gotschlich EC. A simplification of the radioactive antigen binding test by a double label technique. J Immunol 1971;107:910-1.
41. Carlone GM, Perkins BA, Popovic T, et al. Haemophilus influenzae type B, Neisseria meningitidis, streptococcal pneumoniae and corynebacterium diphtheria vaccine. In: Rose NR, Hamiltoin RG, Detrick B, editors. Manual of clinical laboratory immunology. 6th edition. Washington, DC: ASM Press; 2002. p. 420-2.
42. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcus in human volunteers. J Exp Med 1969; 129:1367-84.
43. Goldschneider I, Lepow ML, Gotschlich EC. Immunogenicity of the group A and group C meningococcal polysaccharides in children. J Infect Dis 1971;125:509-19.
44. Brandt BL, Artenstein MS. Duration of antibody responses after vaccination with group C Neisseria meningitidis polysaccharide. J Infect Dis 1975;131:569-75.
45. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975;56: 1536-47.
46. Artenstein MS, Brandt BL. Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide. J Immunol 1975;115:5-7.
47. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractomess in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998;178:870-4.
48. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977;60:673-80.
49. Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970;282:417-24.
50. Gold R, Artenstein MS. Meningococcal infections, field trial of group C meningococcal polysaccharide vaccine in 1960-1970. Bull World Health Organ 1971;45:279-82.
51. Masterton RG, Youngs ER, Wardle JC, Croft KF, Jones DM. Control of an outbreak of group C meningococcal meningitis with a polysaccharide vaccine. J Infect Dis 1988;17:177-82.
52. Taunay AE, Feldman RA, Bastos C, et al. Avaliacae do efeito protector de vacina polissacaridica antimeningococica do groupo C, Em criancas DE6 A36 meses [in Italian]. Rev Inst Adolfo Lutz 1978;38:77-82.
53. Amata NV, Finger E, Gotschlich EC, Feldman RA, et al. Serologic response to serogroup C meningococcal polysaccharide in Brazilian preschool children. Rev Inst Med Trop Sao Paulo 1974;16:149-53.
54. McCormick JB, Gusmao HH, Nakamura S, et al. Antibody response to serogroup A and C meningococcal vaccines in infants born to mothers vaccinated during pregnancy. J Clin Invest 1980;65:1141-4.
55. DeWals P, Dionne M, Douville-Fradet M, Boulianne N, Drapeau J, De Serres G. Impact of a mass immunization campaign against serogroup C meningococcus in the province of Quebec, Canada. Bull World Health Organ 1996;74:407-11.
56. King WJ, MacDonald NE, Wells G, Huang J, Allen UA, Chan F, et al. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children. J Pediatr 1996;128:196-202.
57. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA 1995;273:383-9.
58. Rosenstein N, Levine O, Taylor J, et al. Persistant serogroup C meningococcal disease outbreak in a vaccinated population, Gregg County, Texas (ABS). Presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 15-18, 1996.
59. Artenstein MS, Branche Jr WC, Zimerly JG, et al. Meningococcal infections-3 studies of group A polysaccharide vaccines. Bull World Health Organ 1971;45:283-6.
60. Makela PH, Kayhty H, Weckstrom P, et al. Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet 1975;2:883-6.
61. Pinner RW, Onyango F, Perkins BA, et al. Epidemic meningococcal disease in Nairobi, Kenya in 1989. J Infect Dis 1992;66:359-64.
62. Greenwood AM, Greenwood BM, Bradley AK, Ball PA, Gilles HM. Enhancement of the immune response to meningococcal polysaccharide vaccine in a malaria endemic area by administration of chloroquin. Ann Trop Med Parasitol 1981;75:261-3.
63. Peltola H, Makela PH, Kayhty H, Jousimies H, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977;297:686-91.
64. Lennon D, Gellin B, Hood D, Voss L. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr Infect Dis J 1992;11:617-23.
65. Gold R, Lepow ML. Present status of polysaccharide vaccines in the prevention of meningococcal disease. Adv Pediatr 1976;23:71-87.
66. Kayhty H, Karanko V, Peltola H, Sarna S, Makela PH. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for 3 years in infants and children. J Infect Dis 1980;142:861-8.
67. Ceesay SJ, Allen SJ, Merron A, et al. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis 1993;167:1212-6.
68. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med 1969;129:1385-95.
69. Hassan King MK, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect Dis 1988;16(1):55-9.
70. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States 2002-2003. MMWR Morb Mortal Wkly Rep 2002;51:904-8.
71. Lieberman JM, Chiu SS, Wong VK, Partridge S, Chang SJ, Chiu CY, et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: a randomized controlled study. JAMA 1996;275:1499-503.
72. Twumasi Jr PA, Kumah S, Leach A, O'Dempsey TJ, et al. A trial of group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995; 171:632-8.
73. Gold R, Lepow ML, Goldschneider I, Draper TL, et al. Immune response of human infants to polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis 1977;136:531-5.
74. Joseph H, Ryalt R, Bybel M, et al. Immunogenicity and immunologic priming of the serogroup A portion of a bivalent meningococcal A/C conjugate vaccine in 2 year old children. J Infect Dis 2003;187:1142-6.
75. Leach A, Twumasi PA, Kumah S, Banya WS, Jaffar S, Forrest BD, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997;175:200-4.
76. Rennels MB, Edwards KM, Keyserling HI, Reisinger KS, et al. Immunogenicity and safety of conjugate meningococcal vaccine in infants [abstract]. Pediatr Res 1996;39:183A.
77. Rennels M, Edwards K, Keyserling H, et al. Immunogenicity and safety of a 4th dose of meningococcal group C oligosaccharide conjugated to CRM 197 (Wyeth-Lederle) vaccine [abstract #601]. Proceedings of 35th Annual Meeting of the Infectious Diseases Society of America. 1997. p. 183.
78. Fairley CK, Begg N, Borrow R, et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996;174:1360-3.
79. Richmond P, Goldblatt D, Fusco P. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 2000;18:641-6.
80. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunogenic hyporesponsiveness in adults that is overcome with meningococcal conjugate. J Infect Dis 2001;181:761-4.
81. Borrow R, Southein J, Andrews N, et al. Comparison of antibody kinetics following serogroup C conjugate vaccine between health adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine naïve controls. Vaccine 2001;19:3043-50.
82. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the United Kingdon. J Med Microbiol 2002;51:717-22.
83. Maiden CJ, Stuart JM. UK meningococcal carriage group. Carriage of serogroup C meningococci one year after meningococcal C conjugate polysaccharide vaccine [research letter]. Lancet 2002;359:1829-30.
84. Campbell JD, Edelman R, King JC, et al. Safety, reactogenicity and immunogenicity of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002;186:1848-51.
85. Vermont C, Dobbelsteen VG. Neisseria meningitidis serogroup B: laboratory correlates of protection. FEMS Immunol Med Microbiol 2002;34:89-96.
86. Poolman JT. Development of a meningococcal vaccine. Infect Agents Dis 1995;4:13-28.
87. deMoraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-8.
88. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
89. Peeters CC, Rumke HC, Sundermann LC, et al. Phase 1 clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996;13:1009-15.
90. Plesed JS, Harris SL, Wright C. High conserved Neisseria meningitidis inner core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J Infect Dis 2003;187:1223-34.